Table 1.
Samples Used in the Study
| Code of Sample | Characteristic | ||
|---|---|---|---|
| Prodrug Used | Prodrug Loading (%) | Type | |
| MSNs | No | No | Nanoparticles (NPs) |
| MSNs-NH2 | No | No | Modified nanoparticle (amino-modified NPs) |
| MSNs-NH2-SH | Shikimic acid | 3% | Nanoformulation |
| MSNs-NH2-QR | Quercetin | 22.4% | Nanoformulation |
| MSNs-NH2-SH-QR1 | Shikimic acid and quercetin | 24.4% | Combined nanoformulation |
| MSNs-NH2-SH-QR2 | shikimic acid and quercetin | 24.4% | Combined nanoformulation. Twice higher nanoparticle concentration than for MSNs-NH2-SH-QR1 |
| SH | Shikimic acid | Not relevant | Prodrug |
| QR | Quercetin | Not relevant | Prodrug |
| SH/QR mix.1 | Simple mixture | Not relevant | Mixed prodrugs |
| SH/QR mix.2 | Simple mixture | Not relevant | Mixed prodrugs |
Notes: Nanoformulation means the prodrug(s) loaded with MSNs.
Abbreviations: MSNs, mesoporous silica nanoparticles; MSNs-NH2, MSNs modified amino groups; MSNs-NH2-SH, MSNs-NH2 loaded SH; MSNs-NH2-QR, MSNs-NH2 loaded QR; MSNs-NH2-SH-QR1, MSNs-NH2 loaded SH and QR; MSNs-NH2-SH-QR2 was used in twice amount; SH/QR mix.1, mixture of SH and QR; SH/QR mix.2, mixture of SH and QR used in twice amount; SH pure, shikimic acid; QR pure, quercetin.